Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cagliari
Clinical trial register · Italy

Clinical Trials in Cagliari, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Cagliari8 Fondazione Italiana Linfomi - ETS7 AstraZeneca5 F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore4 IRCCS Azienda Ospedaliero-Universitaria di Bologna4
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Cagliari

124 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
NCT07696507Low Back Pain, Chronic Low Back Pain (CLBP)
Axon srl
Not applicable
69
Cagliari, Cosenza, Naples
2026-09
Recruiting
Guerbet
Phase 3
315
Bergamo, Cagliari, Chieti, Milan, Roma, Treviso
2026-07-28
Recruiting
Fondazione Italiana Linfomi - ETS
Phase 3
518
Alessandria, Avellino, Aviano, Bergamo, Brescia, Cagliari, Candiolo, Catania
2026-07-10
Recruiting
Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial
NCT07671963Periodontitis (Stage 3), Minimally Invasive Surgical Procedures, Bone Substitutes
University of Belgrade
Not applicable
30
Cagliari
2026-07-01
Not yet open
Fondazione Italiana Linfomi - ETS
Not applicable
170
Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan
2026-05
Recruiting
ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms
NCT07522008Chronic Kidney Disease 5D, Uremia; Chronic
Azienda Ospedaliera Brotzu
Observational
120
Cagliari
2026-03-15
Not yet open
Danish Multiple Sclerosis Hospitals
Phase 2
94
Cagliari
2026-02-01
Recruiting
Eli Lilly and Company
Phase 3
150
Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova
2026-01-12
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Acireale, Cagliari, Florence, Foggia, Genova, Merano, Naples, Sassari
2026-01-08
Not yet open
Heart Care Foundation
Not applicable
240
Orbassano, Torino, Acquaviva delle Fonti, Ancona, Arzignano, Benevento, Cagliari, Caserta
2025-12-11
Active, closed
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,200
Bologna, Cagliari, Catanzaro, Florence, Milan, Palermo, Potenza, Roma
2025-12-09
Recruiting
Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis
NCT07505355Multiple Sclerosis, Healthy Controls Group - Age and Sex-matched
Hasselt University
Observational
100
Cagliari
2025-11-10
By invitation
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
NCT07343661EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma
DrugsNucala·Mepolizumab
Azienda Ospedaliero Universitaria di Cagliari
Phase 4
90
Cagliari
2025-10-17
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Cagliari, Milan, Monza, Negrar-Verona, Roma, Rozzano, Torino
2025-10-03
Not yet open
LUpus Eritematoso Sistemico NETwork and Registry
NCT07175610Systemic Lupus Erythematous (SLE)
Società Italiana di Allergologia, Asma e Immunologia Clinica
Observational
1,500
Ancona, Bari, Battipaglia, Cagliari, Florence, Mantua, Milan, Naples
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
L’Aquila, Cagliari, Rozzano, Baggiovara, Bologna, Chieti, Naples, Roma
2025-09-22
Recruiting
Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL)
NCT07677631Fibromyalgia, Chronic Pain, Nociplastic Pain
University of Bari
Observational
425
Bari, Bologna, Cagliari, Naples, Verona
2025-09-10
Not yet open
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides
NCT07046663Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Fondazione Italiana Linfomi - ETS
Observational
190
Ancona, Bergamo, Bologna, Brescia, Cagliari, Catania, Florence, Genova
2025-09
Active, closed
REal-life ON PARKinson's - ITaly (REONPARK-IT)
NCT07403799Parkinson Disease
Bial - Portela C S.A.
Observational
200
Bari, Brescia, Cagliari, Catanzaro, Chieti, Genova, Messina, Milan
2025-07-08
Active, closed
AstraZeneca
Observational
315
Cittadella (PD), Montebelluna (TV), Aosta, Avellino, Bari, Bergamo, Brescia, Cagliari
2025-06-25
Recruiting
BeOne Medicines
Phase 3
630
Bari, Cagliari, Catania, Ferrara, Milan, Modena, Pagani
2025-06-11
Not yet open
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
100
Bari, Bologna, Brescia, Cagliari, Ferrara, Florence, Genova, Messina
2025-06-01
Not yet open
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
600
Orbassano, Bari, Bologna, Cagliari, Cuneo, Ferrara, Florence, Genova
2025-06-01
Recruiting
Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others
NCT07498452REM Sleep Behavior Disorder, Isolated REM Sleep Behavior Disorder
Universita di Verona
Observational
150
Bologna, Genoa, Milan, Pavia, Cagliari, Troina, Pisa, Verona
2025-05-06
Not yet open
Gelscom SAS
Phase 2/3
60
Cagliari, Siena
2025-04
Recruiting
AstraZeneca
Phase 3
400
Bari, Bergamo, Brescia, Cagliari, Catanzaro, Genoa, Milan, Modena
2025-03-28
Recruiting
FB Vision S.p.A
Not applicable
74
Cagliari, Catanzaro
2025-03-26
Recruiting
AstraZeneca
Phase 3
840
Cagliari, Florence, Milan, Naples, Padova, Rozzano, Torino, Tricase
2025-03-01
Recruiting
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
NCT06588868Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS
Observational
400
Ancona, Bari, Bologna, Brescia, Cagliari, Catania, Florence, Genova
2025-02-27
Recruiting
Gruppo Oncologico del Nord-Ovest
Phase 2
67
Cagliari, Catania, Florence, Milan, Rozzano, Naples, Roma
2025-02-20
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
Bologna, Brescia, Cagliari, Genova, Padova
2025-02-20
By invitation
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy
NCT06875739Neurodegenerative Disorders, Parkinson Disease, Alzheimer Disease, Parkinsonian Disorders
Fondazione Don Carlo Gnocchi ETS
Observational
310
Cagliari, Florence, Milan
2025-02-14
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
60
Bologna, Bari, Cagliari, Catania, Catanzaro, Florence, Genova, Messina
2025-02-12
Recruiting
Dr. Inge Winter
Phase 3
418
Brescia, Cagliari, Naples, Turin
2025-02-11
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Cagliari, Florence, Milan, Pavia, Perugia
2025-02-04
Recruiting
University of Cagliari
Not applicable
180
Cagliari
2025-02-03
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Bologna, Cagliari, Florence, Milan, Naples, Padova, Palermo, Pavia
2025-01-28
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Bologna, Cagliari, Genova, Milan, Naples, Pisa, Roma, Siena
2024-12-17
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Bergamo, Cagliari, Florence, Genova, Livorno, Milan, Modena, Monza
2024-12-05
Recruiting
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
300
Bari, Bologna, Cagliari, Ferrara, Florence, Foggia, Genova, Messina
2024-11-04
Recruiting
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
600
Alessandria, Bari, Bologna, Brescia, Cagliari, Ferrara, Florence, Foggia
2024-11-04
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
200
Meldola, Bologna, Cagliari, Naples
2024-10-30
Active, closed
Fondazione Italiana Linfomi - ETS
Observational
241
Milan, Aviano, Bergamo, Bologna, Brescia, Cagliari, Cuneo, Florence
2024-10-30
Active, closed
Merus B.V.
Phase 3
699
Ancona, Brescia, Cagliari, Meldola, Milan, Naples, Rome, Rozzano
2024-09-25
Recruiting
Dr. Inge Winter
Phase 3
418
Brescia, Cagliari, Naples, Turin
2024-08-31
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Alessandria, Asti, Bari, Bergamo, Bologna, Cagliari, Chieri, Chieti
2024-08-30
Recruiting
Non-pharmacological Care for Depression in Cancer Patients Using VR and TMS
NCT06589544Depressive Symptoms, Quality of Life, Cognitive Impairment
University Hospital of Ferrara
Not applicable
100
Ferrara, Cagliari
2024-08-21
Recruiting
University of Cagliari
Observational
80
Cagliari, Novedrate, Troina, Messina, Palermo
2024-08-08
Recruiting
Dr. Inge Winter
Phase 4
418
Brescia, Cagliari, Naples, Turin
2024-08-01
Recruiting
Istituto Auxologico Italiano
Observational
5,000
Acri, Ancona, Bari, Bergamo, Bologna, Cagliari, Catania, Corigliano-Rossano
2024-06-01
Active, closed
Università Vita-Salute San Raffaele
Not applicable
400
Cagliari, Milan
2024-05-16
Recruiting
CSL Behring
Phase 2/3
3,110
Bologna, Brescia, Cagliari, Caserta, Catania, Ferrara, Florence, Foggia
2024-04-27
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti
2024-04-16
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Agrigento, Bologna, Brescia, Cagliari, Florence, Milan, Padova, Parma
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Bologna, Cagliari, Catanzaro, Milan, Negrar, Padova, Palermo, Roma
2024-03-27
Recruiting
Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population
NCT06870006Eating Disorders, Mood Disorders in Children and Adolescents, Psychotic Disorder, QTc Intervals Changes
Meyer Children's Hospital IRCCS
Observational
100
Troina, Florence, Calambrone, Bologna, Cagliari, Messina
2024-01-01
Active, closed
Bioprojet
Phase 2
62
Bologna, Bosisio Parini, Cagliari, Calambrone, Foggia, Messina, Naples, Pavia
2023-12-20
Recruiting
Fondazione Italiana Linfomi - ETS
Phase 3
190
Sassuolo, Alessandria, Avellino, Aviano, Bari, Biella, Brescia, Cagliari
2023-12-14
Active, closed
AnaptysBio, Inc.
Phase 2
132
Bologna, Cagliari, Catania, Legnano, Milan, Pavia, Rozzano, San Donato
2023-12-04
Active, closed
Social Participation and Healthy Aging
NCT06162871Healthy Aging
University of Cagliari
Not applicable
20
Cagliari
2023-12-01
Recruiting
Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)
NCT06001645Acute Respiratory Distress Syndrome, Barotrauma
Università Vita-Salute San Raffaele
Observational
110
Cagliari, Milan, Pisa, Potenza
2023-11-27
Active, closed
Pfizer
Phase 3
1,571
L’Aquila, Florence, Milan, Roma, Rome, Cagliari
2023-11-08
Active, closed
Efficacy of tDCS in Degenerative Ataxia
NCT07250321Ataxia, Cerebellar, Ataxia - Genetic Diagnosis - Unknown, Ataxia, Spinocerebellar, Ataxias, Hereditary
University of Cagliari
Not applicable
16
Cagliari
2023-10-09
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Roma, Ancona, Bari, Cagliari, Catania, Ferrara, Florence, Milan
2023-09-13
Recruiting
Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
NCT06119269Chronic Myeloid Leukemia, Chronic Phase
University of Pisa
Observational
100
Cagliari, Milan, Naples, Pisa, Roma
2023-08-02
Recruiting
GlaxoSmithKline
Phase 3
892
Cagliari, Genova, Milan, Naples, Padova, Pisa, Reggio Emilia, Roma
2023-08-01
Active, closed
Swedish Orphan Biovitrum
Observational
165
Bari, Bassano del Grappa, Bologna, Cagliari, Florence, Milan, Novara, Reggio Calabria
2023-06-26
Recruiting
H. Lundbeck A/S
Phase 3
315
Cagliari, Genoa, Milan, Pavia, Pisa, Rome
2023-06-08
Recruiting
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06708429Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer)
San Raffaele University
Observational
300
Milan, Palermo, Cagliari
2023-06-01
Active, closed
Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia
Observational
140
Cagliari
2023-05-30
Active, closed
Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia
Observational
350
Cagliari
2023-04-30
Recruiting
Meyer Children's Hospital IRCCS
Observational
90
Bagno a Ripoli, Borgo San Lorenzo, Forlì, Legnago, Bologna, Bolzano, Cagliari, Empoli
2023-04-05
Active, closed
AstraZeneca
Observational
551
Naples, Cona, Udine, Rome, Brescia, Milan, Turin, Cagliari
2023-02-27
Not yet open
University of Cagliari
Observational
256
Cagliari
2023-01-01
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Ancona, Bologna, Brescia, Cagliari, Caserta, Catanzaro, Cinisello Balsamo, Florence
2022-12-27
Recruiting
Survival and Prognostic Factors of Squamous Cell Carcinoma of the Nasal Vestibule
NCT05693116Nasal Vestibule Carcinoma, Rhinectomy, Nasal Vestibule, Squamous Cell Carcinoma
Istituto Clinico Humanitas
Observational
300
Rozzano, Cagliari, Milan, Varese
2022-12-01
Recruiting
Prognotic Role of CMR in Takotsubo Syndrome
NCT06277297Takotsubo Cardiomyopathy, Machine Learning, Magnetic Resonance Imaging
University of Cagliari
Observational
350
Cagliari
2022-11-09
Recruiting
National Database on Primary Sclerosing Cholangitis (PSC)
NCT05618145Primary Sclerosing Cholangitis
University of Milano Bicocca
Observational
6,000
Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte
2022-10-21
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Cosenza
2022-09-08
Recruiting
Fondazione IRCCS Policlinico San Matteo di Pavia
Observational
1,000
Legnano, Orbassano, Ancona, Bari, Bergamo, Brescia, Cagliari, Cosenza
2022-07-13
Recruiting
Pirfenidone to Prevent Fibrosis in Ards.
NCT05075161Acute Respiratory Distress Syndrome (ARDS)
DrugPirfenidone
Università Vita-Salute San Raffaele
Phase 3
130
Milan, Alessandria, Bari, Brescia, Cagliari, Merano, Palermo, Pisa
2022-06-01
Recruiting
Società Italiana Talassemie ed Emoglobinopatie
Observational
10,000
Cagliari
2022-02-01
Recruiting
Mario Negri Institute for Pharmacological Research
Observational
2,500
Alessandria, Arezzo, Baggiovara, Bergamo, Bologna, Brescia, Cagliari, Correggio
2022-01-03
Active, closed
Società Italiana Talassemie ed Emoglobinopatie
Observational
1,000
Torino, Cagliari, Ferrara, Genova, Milan, Naples, Palermo, Roma
2022-01-01
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
194
Brindisi, Cagliari, Ferrara, Genova, Milan, Modena, Naples, Orbassano
2021-12-20
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
101
Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Castelfranco Veneto
2021-12-03
Recruiting
H. Lundbeck A/S
Phase 3
600
Rome, Genoa, Milan, Cagliari, Florence, Pisa, Pavia
2021-12-01
Active, closed
Agios Pharmaceuticals, Inc.
Phase 3
258
Brindisi, Cagliari, Ferrara, Genova, Milan, Modena, Naples, Orbassano
2021-11-30
Recruiting
Niguarda Hospital
Phase 3
288
Ancona, Bergamo, Bologna, Brescia, Cagliari, Chieti, Florence, Genova
2021-10-07
Recruiting
H. Lundbeck A/S
Phase 3
285
Pavia, Rome, Milan, Cagliari, Genoa
2021-06-30
Active, closed
Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS
NCT05027984Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease
Centro per la Lotta Contro l'Infarto - Fondazione Onlus
Not applicable
1,425
Ascoli Piceno, Acquaviva delle Fonti, Bari, Bergamo, Benevento, Bologna, Cagliari, Aversa
2021-06-30
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Avellino, Biella, Cagliari, Candiolo, Lido di Camaiore, Meldola, Milan, Naples
2021-06-24
Active, closed
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
100
Bologna, San Giovanni Rotondo, Bari, Cagliari, Novara, Palermo, Reggio Emilia, Terni
2021-05-20
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Observational
496
Alessandria, Ponderano, Cagliari, Catania, Milan, Palermo, Padova, Pescara
2020-12-01
Active, closed
AbbVie
Phase 3
527
Bologna, Genoa, Milan, Rho, Rome, Negrar, Cagliari, Palermo
2020-09-30
Recruiting
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
University of Siena
Observational
3,500
Siena, Bari, Bolzano, Brescia, Cagliari, Catania, Catanzaro, Chieti
2020-08-06
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational
321
Cona, Alessandria, Bari, Cagliari, Catania, Catanzaro, Cosenza, Florence
2020-07-24
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational
572
Alessandria, Asti, Bari, Bologna, Cagliari, Florence, Milan, Modena
2020-05-29
Recruiting
University of Cagliari
Observational
300
Oggebbio, Cagliari
2020-05-25
Recruiting
FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).
NCT07359651Necrotizing Fascitis, Fournier Gangrene, Fournier's Gangrene, Soft Tissue Infections
University of Cagliari
Observational
300
Cagliari, Milan, Monza, Roma
2020-01-01
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Bari, Bolzano, Cagliari, Careggi, Catania, Modena, Siena, Turin
2019-12-17
Active, closed
Gruppo Italiano Trapianto di Midollo Osseo
Phase 2
120
Cagliari, Naples, Ancona, Bari, Bologna, Brescia, Cuneo, Florence
2019-12-06
Recruiting
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2
89
San Giovanni Rotondo, Bari, Bergamo, Bologna, Cagliari, Catania, Florence, Genova
2019-10-09
Active, closed
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT03697512Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
DrugsIbrutinib·Rituximab
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
175
Ponderano, Milan, Torino, Ancona, Bari, Brescia, Cagliari, Pavia
2019-09-27
Recruiting
National Database on Primary Biliary Cholangitis
NCT05151809Primary Biliary Cholangitis
University of Milano Bicocca
Observational
6,000
Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte
2019-09-19
Recruiting
University Hospital Muenster
Phase 3
683
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cona
2019-08-23
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Florence, Allessandria, Bologna, Brindisi, Cagliari, Ferrara, Genoa, Lecce
2019-08-12
Active, closed
Fondazione Italiana Linfomi - ETS
Phase 2
75
Castelfranco Veneto, Alessandria, Ancona, Avellino, Aviano, Bari, Brescia, Cagliari
2019-07-02
Active, closed
Fondazione EMN Italy Onlus
Phase 3
84
Alessandria, Ancona, Ascoli Piceno, Bari, Bergamo, Bolzano, Brescia, Cagliari
2019-07-01
Active, closed
Sanofi
Observational
955
Torrette Di Ancona, Terracina, Rome, Bari, Brescia, Cagliari, Genova, L’Aquila
2019-06-11
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Cagliari, Cremona, Naples, Padova, Pisa, Potenza, Reggio Emilia, Roma
2019-03-21
Recruiting
Martin Schrappe
Phase 3
5,000
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Catanzaro
2018-07-15
Active, closed
Janssen Research & Development, LLC
Phase 3
120
Ancona, Bologna, Cagliari, Padova, Reggio Emilia
2018-07-11
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Bologna, Cagliari, Cento, Messina, Milan, Padova, Roma, Rome
2018-04-13
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational
530
Ancona, Bologna, Brindisi, Cagliari, Catania, Catanzaro, Cona, Cosenza
2017-11-13
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Bari, Benevento, Bologna, Brindisi, Cagliari, Florence, Genova, Latina
2017-09-12
Active, closed
Acerta Pharma BV
Phase 3
533
Bologna, Cagliari, Cona, Florence, Meldola, Milan, Modena, Ravenna
2015-07-28
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
112
Alessandria, Ancona, Aviano, Biella, Bolzano, Cagliari, Catania, Genova
2013-12
Active, closed
Bristol-Myers Squibb
Observational
2,555
Pesaro, Ancona, Cagliari, Florence, Lecce, Messina, Milan, Naples
2012-06-13
Active, closed
Sentinel Node Vs Observation After Axillary Ultra-souND
NCT02167490Early Stage Breast Carcinoma
European Institute of Oncology
Not applicable
1,560
Bolzano, Brescia, Cagliari, Castellanza, Como, Mantua, Milan, Naples
2012-01
Active, closed
Associazione Qol-one
Phase 2
174
Alessandria, Ancona, Asti, Avellino, Bari, Brindisi, Cagliari, Cosenza
2011-06-11
Recruiting
Global Registry and Natural History Study for Mitochondrial Disorders
NCT05554835Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO
LMU Klinikum
Observational
6,000
Bologna, Brescia, Cagliari, Florence, Genova, Messina, Milan, Pisa
2009-02-01
Recruiting
Pompe Pregnancy Sub-Registry
NCT00567073Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Genzyme, a Sanofi Company
Observational
20
Florence, Milan, Padua, Rome, Brescia, Cagliari, Genova, Messina
2007-06-18
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Gussago, Cona, Florence, Milan, Padua, Rome, Brescia, Cagliari
2004-09-15
Rows per page Showing 1–124 of 124
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/cagliari

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 124 of those studies with a site in Cagliari.

How many clinical trials are recruiting in Cagliari?

67 of the 124 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 10 have not yet opened recruitment, 45 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cagliari), 124 studies
PhaseStudiesRecruitingShare
Observational543143.5%
Phase 3362329%
Phase 213310.5%
Not applicable1249.7%
Phase 2/3644.8%
Phase 4322.4%

Most active sponsors

Lead sponsors with the most studies (Cagliari)
Lead sponsorStudiesRecruiting
University of Cagliari85
Fondazione Italiana Linfomi - ETS73
AstraZeneca53
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore42
Gruppo Italiano Malattie EMatologiche dell'Adulto40
IRCCS Azienda Ospedaliero-Universitaria di Bologna42
Janssen Research & Development, LLC42
Dr. Inge Winter33
H. Lundbeck A/S33
International Extranodal Lymphoma Study Group (IELSG)30
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.